RESUMO
In the far-field wake of a ship, the intensity of the scattering of bubbles is relatively weak. In addition, the wake is relatively thin, and the hole phenomenon is prominent. Thus, it is difficult to detect the wake at a long distance. On this basis, this paper studies a broadband 1-3 high-performance composite transceiver sub-array for the improved detection of a ship's far wake flow field. The content includes frequency characteristics, transmission performance, power tolerance, the beam width of the transmitting array, and the frequency characteristics, reception performance, and beam width of the receiving array. The frequency bandwidth of the transmission array developed in this paper can reach a value of 180 kHz (the center frequency is 390 kHz). The maximum sound source level can reach a value of 228 dB. In the same frequency band, the sensitivity of the receiving array can reach a value of 184 dB, and the fluctuation is less than 5 dB. Compared with the narrowband 1-3 composite array of the same size, the acoustic performance of this sub-array has obvious advantages. Finally, to improve the effective sound path (before the first interface reflection of the sound wave) of the emitted sound wave in the ship's far-field wake, combined with the speed of the moving carrier and the wide-band detection method of the ship's wake, the configuration method of the detection array for the width and direction of the ship's far-field wake is proposed. The results of this research have an important reference value for the research on broadband 1-3 high-performance composite arrays and their application in the far-field wake detection of ships.
RESUMO
Intravesical instillation of Bacillus Calmette-Guérin has been used as an immunotherapy to treat superficial bladder cancer for almost half a century. In recent years, the approval of several monoclonal antibody treatments has transformed the treatment landscape for patients with muscle-invasive or metastatic uroepithelial carcinoma. The purpose of this study was to conduct a thorough review of immunotherapy in bladder cancer through a bibliometric approach. Publications related to bladder cancer immunotherapy were obtained from the Web of Science Core Collection on July 1st, 2022. We conducted a bibliometric analysis of literature information using CiteSpace IV, VOSviewer, and Scimago Graphica, including co-authorship or co-citation of authors, countries/regions, journals, references, and keyword co-occurrence. There was a total of 2,352 papers included, with the most contributions coming from the United States, China, and Italy. The United States had the highest H-index value and was the leading country in this field. Meanwhile, the number of publications in China was steadily growing. The top three productive researchers were Kamat AM, Necchi A, and Shariat SF, with Powles T as the top co-cited author. Most papers were published by the University of Texas System. The majority of papers in this field were published in Urologic Oncology Seminars and Original Investigations and European Urology was the most influential journal with the highest H-index. The tumor microenvironment and complete molecular characterization may still be the frontier in this research area, allowing us to obtain a better understanding of the pathogenesis and clinical prognosis of bladder cancer. More research are conducted to identify clinically meaningful biomarkers that may provide opportunities for the personalization of bladder cancer therapy. This study provides clinicians and researchers with an overview and helpful guidance on how to choose the research direction and management of bladder cancer immunotherapy.